Julian Schardt

Julian Schardt

Auto-generated profile, based on publicly available information

Julian Schardt

Universitätsklinik für Medizinische Onkologie, Inselspital, Bern, Schweiz

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 1999 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CKChristoph A. Klein
Christoph A. Klein
OSOleg Schmidt-Kittler
Oleg Schmidt-Kittler
JSJulian A. Schardt
Julian A. Schardt
KPKlaus Pantel
Klaus Pantel
MSMichael R. Speicher
Michael R. Speicher
GRGert Riethmüller
Gert Riethmüller
A PCR strategy is described for global amplification of DNA from a single eukaryotic cell that enables the comprehensive analysis of the whole genome. By comparative genomic hybridization, not only gross DNA copy number variations, such as monosomic X and trisomic 21 in single male cells and cells from Down’s syndrome patients, respectively, but multiple deletions and amplifications characteristic for human tumor cells are reliably retrieved. As a model of heterogeneous cell populations exposed to selective pressure, we have studied single micrometastatic cells isolated from bone marrow of cancer patients. The observed congruent pattern of comparative genomic hybridization data, loss of heterozygosity, and mutations as detected by sequencing attests to the technique’s fidelity and demonstrates its usefulness for assessing clonal evolution of genetic variants in complex populations.

1 September 2005 in Cancer Cell
Verified
Journal Article
Closed access
JSJulian A. Schardt
Julian A. Schardt
MMManfred Meyer
Manfred Meyer
CHClaudia H. Hartmann
Claudia H. Hartmann
FSFalk Schubert
Falk Schubert
OSOleg Schmidt-Kittler
Oleg Schmidt-Kittler
CKChristoph A. Klein
Christoph A. Klein

1 November 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Thomas PabstThomas Pabst
Thomas Pabst
MEMarianne Eyholzer
Marianne Eyholzer
SHSimon Haefliger
Simon Haefliger
JSJulian Schardt
Julian Schardt
BMBeatrice U. Mueller
Beatrice U. Mueller
Purpose: The transcription factor CCAAT/enhancer binding protein-α (CEBPA) is crucial for normal myeloid differentiation. Mutations in the CEBPA gene are found in subsets of patients with acute myeloid leukemia (AML). Recently, three families were reported in whom several family members had germline CEBPA mutations and subsequently developed AML. Whereas familial AML is considered a rare event, the frequency of CEBPA germline mutations in AML is not known. Patients and Methods: In this study, we screened 187 consecutive AML patients for CEBPA mutations at diagnosis. We detected 18 patients (9.6%) with CEBPA mutations. We then analyzed remission samples and constitutive DNA from these patients. Results: We found that two (11.1%) of 18 AML patients with CEBPA mutations carried a germline N-terminal frameshift CEBPA mutation. Interestingly, additional members in the families of both of these patients have been affected by AML, and the germline CEBPA mutations were also observed in these patients. Additional somatic mutations in AML patients with germline CEBPA mutations in the two families comprised in-frame C-terminal CEBPA mutations in two patients, two nonsilent CEBPA point mutations in one patient, and monosomy 7 in one patient. Conclusion: This study shows, for the first time to our knowledge, that germline CEBPA mutations are frequently observed among AML patients with CEBPA mutations. Including the families with germline CEBPA mutations reported previously, additional somatic CEBPA mutations represent a frequent second event in AML with germline CEBPA mutations. Our data strongly indicate that germline CEBPA mutations predispose to AML and that additional somatic CEBPA mutations contribute to the development of the disease.

15 August 2005 in Blood
Verified
Journal Article
Closed access
PDF file
DHDaniel Helbling
Daniel Helbling
BMBeatrice U. Mueller
Beatrice U. Mueller
NTNikolai A. Timchenko
Nikolai A. Timchenko
JSJulian Schardt
Julian Schardt
MEMyriam Eyer
Myriam Eyer
TPThomas Pabst
Thomas Pabst
The pericentric inversion of chromosome 16, inv(16)(p13q22), is associated with acute myeloid leukemia (AML) subtype M4Eo that is characterized by the presence of myelomonocytic blasts and atypical eosinophils. This rearrangement fuses the CBFB and MYH11 genes, with the latter encoding the smooth muscle myosin heavy chain (SMMHC). The myeloid transcription factor CCAAT/enhancer-binding protein α (CEBPA) is crucial for normal granulopoiesis. Alterations of structure and expression of CEBPA have been implicated in particular subtypes of AML. Here, we found that conditional expression of core-binding factor β (CBFB)-SMMHC in U937 cells suppresses CEBPA protein expression and binding activity. However, CEBPA mRNA levels remained unchanged. No differences were detected in CEBPA mRNA levels in patients with inv(16) AML-M4Eo (n = 12) compared to patients with AML with a normal karyotype and M4 subtype (n = 6), whereas CEBPA protein and binding activity were significantly reduced in patients with CBFB-SMMHC. Furthermore, calreticulin, an inhibitor of CEBPA translation, was induced on mRNA and protein level in CBFB-SMMHC patients with AML and after expression of CBFB-SMMHC in the U937-cell system. Inhibition of calreticulin by siRNA restored CEBPA levels. Our results suggest that modulation of CEBPA by calreticulin represents a novel mechanism involved in the differentiation block in CBFB-SMMHC AML. (Blood. 2005;106:1369-1375)

1 July 2002 in The American Journal of Pathology
Verified
Journal Article
Closed access
NSNikolas H. Stoecklein
Nikolas H. Stoecklein
AEAndreas Erbersdobler
Andreas Erbersdobler
OSOleg Schmidt-Kittler
Oleg Schmidt-Kittler
JDJoachim Diebold
Joachim Diebold
JSJulian A. Schardt
Julian A. Schardt
CKChristoph A. Klein
Christoph A. Klein

1 June 2009 in Clinical Cancer Research
Verified
Journal Article
Closed access
JSJulian A. Schardt
Julian A. Schardt
DWDaniel Weber
Daniel Weber
MEMarianne Eyholzer
Marianne Eyholzer
BMBeatrice U. Mueller
Beatrice U. Mueller
TPThomas Pabst
Thomas Pabst
Purpose: The unfolded protein response is triggered by the accumulation of misfolded proteins within the endoplasmic reticulum. Previous studies suggest that the unfolded protein response is activated in some cancer cell lines and involved in tumor development. The role of the unfolded protein response during leukemogenesis is unknown thus far. Experimental Design: Here, we assessed the induction of key effectors of the unfolded protein response in leukemic cells at diagnosis of 105 acute myeloid leukemia (AML) patients comprising all subtypes. We determined the formation of the spliced variant of the X-box–binding protein 1 (XBP1) mRNA, as well as expression levels of calreticulin, GRP78, and CHOP mRNA. Results: The formation of the spliced variant of XBP1s was detectable in 16.2% (17 of 105) of AML patients. Consistent with activated unfolded protein response, this group also had significantly increased expression of calreticulin, GRP78, and CHOP. AML patients with activated unfolded protein response had lower WBC counts, lactate dehydrogenase levels, and more frequently, secondary AML. The incidence of fms-related tyrosine kinase 3 (FLT3) mutations was significantly lower in patients with activated unfolded protein response. In addition, an association was observed between activated unfolded protein response and deletion of chromosome 7. Finally, the clinical course of AML patients with activated unfolded protein response was more favorable with lower relapse rate (P = 0.0182) and better overall (P = 0.041) and disease-free survival (P = 0.022). Conclusions: These results suggest that the unfolded protein response is activated in a considerable subset of AML patients. AML patients with activated unfolded protein response present specific clinical characteristics and a more favorable course of the disease.